Novo Nordisk gains EU approval for FlexTouch®
Novo Nordisk
Novo Nordisk has been granted approval by the European Commission for the new prefilled insulin pen - FlexTouch®. The approval is for NovoRapid® (insulin aspart) and Levemir® (insulin detemir) - both modern insulins currently delivered in FlexPen®. FlexTouch® is the latest prefilled delivery system from Novo Nordisk which offers a new insulin injection experience for users. Current insulin pens require users to inject their insulin in a traditional way - using the force of their thumb to push the button. For some patients this can be difficult.
"Simplicity is the key requirement for any insulin pen," says Dr Tim Bailey, MD, AMCR Institute, US, "everyone benefits when the pen is simple and easy to use - patients, doctors and nurses educating the patients."
FlexTouch® has an easy-touch button which requires very little force to inject the insulin - at any dose. "As FlexTouch® requires a very small force to inject it means that almost any patient can use it" remarks Dr Bailey.
Launch timing of FlexTouch® in specific EU countries is pending local negotiations in each country.
About FlexTouch®
FlexTouch® is a prefilled insulin pen containing 300 units of insulin. It doses in 1 unit increments, from 1 to 80 units. It is compatible with NovoTwist® needles.
NovoTwist® comes in 5 mm (32G Tip) and 8 mm (30G) versions. An audible and tactile 'click' confirms attachment of the needle.
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Follow/Join us on:
Facebook Twitter RSS
Enter your email address:
Subscribe to PharmaNews.eu alerts by Email
(a free e-mail delivery powered by Google).
Sponsored Links World Pharma News
World Pharma News - one of the world's leading web-based pharmaceutical news publications.
www.worldpharmanews.com Advertise here
Who's Online We have 112 guests onlineLatest NewsTrajenta® (linagliptin) receives approval for the treatment of type 2 diabetes in Europe
Novo Nordisk to build new corporate centre in Bagsværd, Denmark
ecancerHub - A New Approach to Cancer Communication
Industry NewsAbbott | Amgen | AstraZeneca | Bayer | Boehringer Ingelheim | Bristol-Myers Squibb | Genzyme | GlaxoSmithKline | Lilly | Merck | Merck KGaA | Novartis | Novo Nordisk | Nycomed | Pfizer | Roche | Sanofi-aventis | Schering-Plough | Shire | ...
Submit News More informationAdvertise / Contact Us
Terms and Conditions
Follow/Join us on:
© PharmaNews.eu All rights reserved.
[x] closeLesezeichen / WeitersagenXWählen Sie aus diesen Feeds:
AOLBloglinesGoogle ReaderMy MSNNetvibesNewsisfreePageflakesYahoo
Kein passender Dienst
.netShoutout100zakladok2 Tag2linkme7Live7.comA1‑WebmarksA97abiAdftyAdifniAeroAll My FavesAmazonAmen Me!AOL MailArmenixArtoAviary CaptureBaangBaiduBeboBentioBiggerPocketsBit.lyBizSugarBleetboxBlinklistBlipBloggerBloggyBlogmarksBlogtrottrBlurpaliciousBobrdobrBonzoBoxBookmarkingNetBookmarky.czBookmerkenBordomBox.netBrainifyBryderi.seBuddyMarksBuzzzyCamyooCardThisCare2ChiqCiripCiteULikeClassicalPlaceCndigColivia.deCommunicateConnoteacOOtopiaCOSMiQCurate.usDeliciousDesignBumpDesignmooDigaCulturaDiggDiggitaDiglogDigoDigThisHostDigzignDiigoDipdiveDoMelhorDostiDotNetKicksDotShareDoubanDraugiem.lvDrimioDropjackDruckenDwelliciousDzoneE-MailEdelightEFactoreKudoselefanta.plEmbarkonseuCliqueiEvernoteextraplayEzySpotFabDesignFabulously40FacebookFarkFarkindaFashiolistaFashion BurnerFAVableFavesfavlogFavoritenFavoritenFavoritusFlakerFloss.proFolkdFormspringFreeDictionaryFresquiFriendFeedFriendsterfunPfwispGabbrGamekickerGiveALinkGlobalGrindGmailGo.vnGood NoowsGoogleGoogle BuzzGoogle ReaderGraveeGreaterDebaterGrono.netHaber.gen.trHacker NewsHadash HotHatenaHealthimizeHedgehogsHelloTxthistoriousHitmarksHot BookmarkHotklixHotmailHTML ValidatorHyvesideaREF!Identi.caihavegotIndex4IndexorInformazioneInstapaperInvestorLinksiOrbixiSocietyiWiWJamespotJappy TickerJoliPrintJumptagsKaboodleKaevurKaixin RepasteKindle ItKipupKiRTSYKledyKommentingLa tafaneraLaaikitLadenzeileLibrerioLifestreamLink NinjaLink-a-GogoLinkedInLinks GutterLinkSharesLinkuj.czLiveJournalLockerBloggerLogger24Mail.ruMarkmeMashbordMawindomeinVZMekusharimMemonicMemori.ruMenéameMessengerMindbodygreenMister WongMoemesto.ruMoikrugmototagzmRcNEtwORKMultiplymyAOLMyHayastanMylinkvaultMyspaceN4GNasza-klasaNetLogNetvibesNetvouzNewsMeBackNewsTrustNewsvineNujijOdnoklassnikiOKNOtizieOneviewOnGoBeeOrkutOyylaPackgPafnetPDF OnlinePDFmyURLPhoneFavsPing.fmPlanypusPlaxoPlurkPochvalPopEditionPosteezyPosterousPrati.baPrintFriendlyPushaQRF.inQuantcastQzoneRead It LaterRedditRediff MyPageRedKumRideFixScoop.atScoop.itSekomanSelect2GetherShavehShe Told MeShirIntarInSimpySina WeiboSlashdotSMISodaHeadSonicoSpeedtileSphinnSpinSnapSpoken To YouSportpostSpreadlyspringpadSquidooStartaidStartlapStoryFollowerstudiVZStuffpitStumbleUponStumpediaStylehiveSvejoSymbalooTaazaShareTagMarks.deTagvnTagzaTarpipeTellMyPoliticianThe Web BlendThinkfinityThisNextThrowpileTip'dTopSitelerTransferrTranslateTuentiTulinqTumblrTusulTvinxTweetMemeTwitterTwitThisTypepadUpnews.itUrlaubswerkURLCaptViadeoVirbVisitezMonSiteVKontaktevKruguDruzeiVOX SocialVybraliSMEVyoomWebnewsWhois LookupWindy CitizenWireFanWordPressWorioWykopXangaXINGY! BookmarksY! MailYammerYardbarkerYemleYiggYoolinkYorumcuyumYoublrYoubookmarksYouMobYuubyZakladok.netZanaticZicZacZingMeZooLooZootool
Fertig
Nachricht gesendet! Erneut teilen
Nachricht wird gesendet ...An: (E-Mail-Adresse)Von: (E-Mail-Adresse)Hinweis: (optional)
255 Zeichen begrenzt
Mehr:AddThisLesezeichen / WeitersagenXEinfacher Weiterempfehlen mit AddThis für Internet Explorer.
GoogleFacebookTwitterE-MailJappy TickerFavoritenRedditDruckenBloggermeinVZ